No Data
Eltes: Notice of partial revisions to the “Financial Results Presentation Materials for the 3rd Quarter of the Fiscal Year Ending 2025/2”
Eltes: (Correction/Numerical Data Correction) Partial Corrections to the “Summary Financial Results for the 3rd Quarter of the Fiscal Year Ending February 2025 [Japanese GAAP] (Consolidated)”
Eltes 9-Mos Loss Y41.00M Vs Net Y9.00M
Immunobiology Research Institute, Genepha, etc.
＜3195＞ Obtained a patent for filling materials containing Genepacapok fibers and feathers and their manufacturing devices and methods. <3558> Changed the Jade Group Shareholder benefit program. <3905> Issuance of the 20th subscription rights by Data Section (with exercise price adjustment provisions, potential number of stocks is 4.4 million shares, raising approximately 3.024 billion yen). <3967> Recorded a special profit of 0.015 billion yen from the sale of investment securities by Eltes. <4058> Completed the acquisition of treasury shares by Toyokumo. <4570> Immunobiological Research Institute.
Eltes: Q3 Earnings FAQ for the Fiscal Year Ending February 2025
Eltes: Confirmation
